Progesterone in HRT: Micronized vs Synthetic

Why HRT includes a progestogen

Systemic estrogen stimulates the uterine lining (endometrium). Without a counterweight, the lining can overgrow, and overgrowth (hyperplasia) can precede endometrial cancer. A progestogen, meaning progesterone or a synthetic progestin, prevents that overgrowth.

The evidence is direct. In the 3-year PEPI trial of 596 women, those on estrogen alone developed simple, complex and atypical hyperplasia at 27.7%, 22.7% and 11.8%, against 0.8%, 0.8% and 0% on placebo. Women on any of the three estrogen-plus-progestogen regimens, including one with micronized progesterone, had hyperplasia rates similar to placebo (PEPI Writing Group, JAMA 1996, PMID: 8569016).

The Menopause Society’s rule follows from this: anyone with a uterus who uses systemic estrogen should receive an adequate progestogen (the one exception is conjugated estrogens combined with bazedoxifene). People without a uterus generally do not need one, and low-dose vaginal estrogen for local symptoms generally does not require one (NAMS 2022, PMID: 35797481).

This article is general information, not medical advice or a dosing recommendation. Decisions about starting, changing or stopping a prescription belong with a licensed clinician who knows your history.

Micronized progesterone vs synthetic progestins

Micronized progesterone is structurally identical to the progesterone the ovaries make. Medroxyprogesterone acetate (the progestin in the WHI combined-therapy arm), norethindrone acetate and levonorgestrel are synthetic progestins (NAMS 2022).

Breast cancer. In the French E3N cohort of 80,377 postmenopausal women, estrogen combined with progesterone carried no measurable increase in invasive breast cancer (relative risk 1.00), while estrogen combined with other progestins carried a relative risk of 1.69 (Fournier et al., Breast Cancer Res Treat 2008, PMID: 17333341). In the WHI randomized trial, conjugated estrogens plus medroxyprogesterone acetate increased breast cancer (Rossouw et al., JAMA 2002, PMID: 12117397).

Clots. The ESTHER case-control study found no clot association for micronized progesterone or pregnane derivatives, but about a four-fold higher risk with norpregnane derivatives (Canonico et al., Circulation 2007, PMID: 17309934).

The caveat. E3N and ESTHER are observational. The Menopause Society notes it is unknown whether oral micronized progesterone regimens change breast cancer, stroke or clot risk in randomized trials, because none has been designed to test it (NAMS 2022).

What the Prometrium label says

Prometrium (progesterone capsules) is FDA-approved to prevent endometrial hyperplasia in postmenopausal women with a uterus who take conjugated estrogens tablets, and to treat secondary amenorrhea (DailyMed). The Menopause Society lists micronized progesterone among the progestogen options for women with a uterus using systemic estrogen; pairing it with estrogens other than conjugated estrogens, such as an estradiol patch, is outside the label’s wording.

The label lists these contraindications: allergy to peanuts (the capsules contain peanut oil) or other ingredients, undiagnosed abnormal genital bleeding, known or suspected breast cancer, current or past blood clots, stroke or heart attack, and liver disease. Prometrium was in the first batch of hormone products whose boxed warning was removed in February 2026 (FDA).

Regimens differ (cyclic or continuous), and the dose and number of days each month matter for protection. The Menopause Society stresses that micronized progesterone must be adequately dosed; your prescriber sets the regimen.

Progesterone creams and other non-oral options

Over-the-counter progesterone creams are not FDA-approved drugs and have not been shown to protect the lining. In a study of 27 women on transdermal estrogen, a progesterone cream at 16, 32 or 64 mg a day produced progesterone levels too low to cause any detectable change in the endometrium (Wren et al., Climacteric 2000, PMID: 11910616). A review explains that creams give low blood levels and unreliable saliva readings, and that any endometrial effect should be judged by biopsy, not blood tests (Stanczyk et al., Menopause 2005, PMID: 15772572).

FDA-approved non-oral routes do exist: combination patches that deliver estradiol with a progestin, and a levonorgestrel intrauterine device, which The Menopause Society describes as an off-label option with limited trial data (NAMS 2022). Compounded progesterone products are not FDA-approved.

Safety: bleeding and side effects to report

• Unscheduled bleeding that starts more than 6 months after beginning combined therapy should be investigated (NAMS 2022), as should any bleeding after menopause that has not been explained.

• The Prometrium label warns of transient dizziness and drowsiness, advises caution when driving, and says to take it as a single daily dose at bedtime.

• Report leg swelling or pain, chest pain, sudden shortness of breath, a breast lump, or sudden vision or speech changes promptly.

This article is general information, not medical advice or a dosing recommendation. Decisions about starting, changing or stopping a prescription belong with a licensed clinician who knows your history.

Comparing providers and costs

Telehealth menopause programs differ in whether they include progesterone in the price and which forms they prescribe. See our women’s HRT comparison, online menopause HRT compared and menopause treatment cost. For estrogen route choices, read estrogen patch vs gel vs pill.

Disclosure

CalcMyPeptide may earn commissions from some telehealth providers on our comparison and review pages, which list only vetted providers whose affiliate programs have approved us or are reviewing our application. This article contains no paid links. How we rank providers and get paid: telehealth disclosure and methodology.